suggested that a therapeutic strategy involving a combination of dasatinib and gemcitabine might overcome gemcitabine resistance, as it would decrease the level of ALDH1A1 expression in pancreatic cancer. This evidence concerns the gene ALDH1A1 and familial pancreatic carcinoma.